SIU Medicine seeks participants for schizophrenia clinical trial study
SPRINGFIELD, IL
A new clinical trial at SIU School of Medicine is testing a treatment that could help people who suffer from schizophrenia.
“Schizophrenia is a complex disorder that affects perception, how people think and interpret the world,” said Dr. Obiora Onwuameze, a psychiatrist at SIU School of Medicine and principal investigator for the study. “It can be disabling if left untreated. Therapies exist to address some of the symptoms, but no approved medications currently exist for the cognitive symptoms associated with schizophrenia.”
The Journey 2 study is testing the effectiveness of a novel medication called valbenazine.
To enroll in the 16-week study, a patient should be
• 18 or older
• Diagnosed with schizophrenia for at least a year
• Receiving antipsychotic therapy, but not clozapine
• Have a history of not responding well to antipsychotic treatment
The participants’ health and safety will be closely monitored throughout the study period. All study-related visits, tests and study drugs will be provided at no cost. Enrolled patients receive a stipend and may be reimbursed for travel.
For more information about the study and enrollment, contact Oladele ‘Dickson’ Owasoyo, PhD, at oowasoyo94@siumed.edu or 217-545-7231. To learn about other clinical trials currently underway at SIU School of Medicine, visit siumed.org/trials.
The mission of SIU School of Medicine is to optimize the health of the people of central and southern Illinois through education, patient care, research and service to the community. SIU Medicine, the health care practice of the school of medicine, includes clinics and offices with more than 300 providers caring for patients throughout the region.
